GLP-1R agonist compound and use thereof
The present disclosure relates to a GLP-1R agonist compound and use thereof, and specifically provides a compound represented by Formula I, or an isotope-labelled compound, a stereoisomer, or a pharmaceutically acceptable salt thereof, and use thereof as a medicament. The compound exhibits excellent agonistic effects and pharmacodynamic properties on GLP-1R and, as a modulator, is useful for manufacturing a medicament for the treatment, amelioration, or prevention of metabolic diseases and related diseases, thus having broad application prospects.
1. A compound, wherein the compound is selected from the group consisting of:
or an isotopic compound or stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein the compound is:
or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 , wherein the compound is:
or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof.
4. The compound according to claim 1 , wherein the compound is:
or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof.
5. The compound according to claim 1 , wherein the compound is:
or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof.
6. The compound according to claim 1 , wherein the compound is:
or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof.
7. The compound according to claim 1 , wherein the compound is:
or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition, comprising the compound of claim 1 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
9. A pharmaceutical composition, comprising the compound of claim 3 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
10. A pharmaceutical composition, comprising the compound of claim 4 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
11. A pharmaceutical composition, comprising the compound of claim 5 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
12. A pharmaceutical composition, comprising the compound of claim 6 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
13. A pharmaceutical composition, comprising the compound of claim 7 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
14. A method for treating disease or condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of the compound of claim 1 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, wherein the disease or condition is diabetes or obesity.
15. A compound having the structure of:
or an isotopic compound or stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition, comprising the compound of claim 15 or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
17. A method for treating disease or condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of the compound of claim 15 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, wherein the disease or condition is diabetes or obesity.
18. A compound having the structure of:
or an isotopic compound or stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition, comprising the compound of claim 18 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
20. A method for treating disease or condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of the compound of claim 18 , or the isotopic compound or stereoisomer thereof, or the pharmaceutically acceptable salt thereof, wherein the disease or condition is diabetes or obesity.